Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study
FDR of individuals with elevated Lp(a) levels have a higher incidence of MACE. Cascade screening could be a feasible strategy to identify FDR at heightened risk.
Authors
- Teresa Hallerbäck
- Gustav Kindborg
- Örjan Lindhe (ORCID: https://orcid.org/0000-0003-2565-7650)
- Emil Hagström (ORCID: https://orcid.org/0000-0003-3221-0144)
- Daniel P. Andersson (ORCID: https://orcid.org/0000-0003-4655-4837)
- Jacinth Yan
- Karin Littmann (ORCID: https://orcid.org/0000-0002-4597-9369)
- Daniel Eriksson Hogling (ORCID: https://orcid.org/0000-0002-9559-2920)
- Henrike Häbel (ORCID: https://orcid.org/0000-0001-5564-4258)
- Jonas Brinck (ORCID: https://orcid.org/0000-0002-1230-6205)
Institutions
- Uppsala University (SE)
- Karolinska University Hospital (SE)
- Uppsala University Hospital (SE)
- Karolinska Institutet (SE)
- Novartis (Sweden) (SE)
Publication Details
- Journal
- European Heart Journal
- Published
- 2025-08-31
- DOI
- https://doi.org/10.1093/eurheartj/ehaf677
- Citations
- 2
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- Amgen
- Sanofi
- Alnylam Pharmaceuticals
- Ultragenyx Pharmaceutical
- Covis Pharma
- Ionis Pharmaceuticals
- Amarin Corporation
- Karolinska Institutet
- Stockholms Läns Landsting
- Svenska Läkaresällskapet